Targeted and Innovative CNS Therapies

Trevena is focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.

Trevena’s novel CNS pipeline includes product candidates aimed at moderate to severe acute pain, migraine, opioid use disorder, and other CNS indications. The company is also developing a new chemical entity as a potential treatment for acute lung injury and acute respiratory distress syndrome (ARDS) associated with COVID-19.  All of the company’s assets have unique mechanisms of action (MOA) that are designed to optimize receptor pharmacology. The result is a pipeline of innovative therapies targeting well-known receptors, but with a potentially more favorable pharmacological profile than current drugs targeting the same receptor class.

Program Molecular Target Therapeutic Target Current Phase PC PH1 PH2 PH3 NDA
Oliceridine Mu receptor Moderate-to-severe acute pain NDA Intravenous PC complete PH1 complete PH2 complete PH3 complete NDA in progress
TRV250 Delta receptor Acute migraine PH1 Oral/Subcutaneous PC complete PH1 in progress PH2 not started PH3 not started NDA not started
TRV734 Mu receptor Opioid use disorder PH1 Oral PC complete PH1 in progress PH2 not started PH3 not started NDA not started
TRV045 S1P receptor CNS disorders PC Oral PC in progress PH1 not started PH2 not started PH3 not started NDA not started
TRV027 AT1 receptor Acute lung injury / ARDS (COVID-19) PH1 Intravenous PC complete PH1 in progress PH2 not started PH3 not started NDA not started
All pipeline assets are Investigational Products not approved by FDA for sale or distribution in the US.

G Protein-coupled Receptors

G protein-coupled receptors (GPCRs) make up the largest family of transmembrane receptors, with approximately 34% of all U.S. Food and Drug Administration (FDA) approved drugs targeting this receptor class.

Typically, GPCR activation engages broad networks of signaling pathways, which are linked to distinct biological responses. Trevena’s compounds employ a functionally-selective MOA at the receptor site, which enables preferential activation of specific signaling pathways while minimizing activation of others.

Through this approach, the company believes it has developed a set of drug candidates with the potential to engage the signaling pathways responsible for therapeutic effect, with reduced activation of the pathways responsible for adverse effects, thus allowing for a more targeted approach to delivering therapeutic benefit.


TRV250 is being developed for the acute treatment of migraine.

Learn More


TRV734 is being developed as a new maintenance therapy for opioid use disorder.

Learn More


TRV045 is a novel S1P modulator in development for the treatment of various CNS disorders.

Learn More


TRV027 is a novel AT1 receptor selective agonist in development for the treatment of COVID-19 acute lung injury / ARDS.

Learn More